CoVID-19 candidate VLA2001 has completed phase I/II clinical trials for patient recruitment

Valneva, a French specialty vaccine company, has completed the patient recruitment process for its inactivated adage form COVID-19 vaccine VLA2001 Phase I/II study and is expected to release preliminary data in April 2021.
150 healthy adults between the ages of 18 and 55 were recruited in a phase I/II study called VLA2001-201.
study was designed to assess the safety, tolerance and immunogenicity of VLA2001 at three dose levels.
last September, Valneva established a partnership with the UK government to supply a total of 190 million doses of COVID-19 vaccine.
as part of the agreement, Valneva will deliver 60 million doses of the vaccine to the UK in the second half of 2021, based on its success in clinical development. Thomas Lingelbach, chief executive of
Valneva, said: "We have reached these two important milestones in such a short period of time and I would like to thank the UK Vaccine Working Group and the National Institutes of Health for their important role in the rapid recruitment of clinical research volunteers.
believe that if we develop our vaccine successfully, we can make a significant contribution to the UK and the region."